Hashimoto Disease and Red Light Therapy Success in 2 Human Trials

Last Updated:

Hashimoto Thyroiditis and Red Light Therapy


Hashimoto's Thyroiditis (HT) is a prevalent autoimmune disorder, characterized by chronic inflammation of the thyroid gland, often leading to hypothyroidism. Traditional management primarily includes hormone replacement therapy, but recent studies have explored the potential of photobiomodulation (PBM) therapy in conjunction with dietary supplements. This article examines two human trials that investigated the efficacy of red light therapy, specifically at wavelengths of 820 and 850 nm, in treating HT.

Study Summaries

Study 1: Impact of Photobiomodulation on T3/T4 Ratio and Quality of Life in Hashimoto Thyroiditis

  • Participants: 350 patients with HT.
  • Method: Divided into two groups, Group 1 received PBM at 850 nm with dietary supplements (vitamin D, iron, selenium), while Group 2 received only dietary supplements.
  • Findings: Group 1 exhibited a substantial increase in triiodothyronine (T3) levels and T3/T4 ratio, a decrease in thyroid peroxidase antibody levels, and reduced hormone replacement needs compared to Group 2. The study highlighted PBM's effectiveness in improving HT-related symptoms, notably in T3/T4 ratio enhancement and levothyroxine dosage reduction.
  • Source: PubMed

Study 2: Efficacy of Combined Photobiomodulation Therapy with Supplements versus Supplements Alone in Restoring Thyroid Gland Homeostasis in Hashimoto Thyroiditis

  • Participants: 74 female subjects, aged between 20 and 50.
  • Method: Group 1 received PBM (820 nm, 200 mW power output, 20 s per point, 32 J/cm² fluence) and supplements, whereas Group 2 received only supplements.
  • Findings: Significant improvements in Group 1 over Group 2 in weight loss, BMI reduction, hip and waist circumference, waist/hip ratio, TSH, antiTPO, antiTG levels, and LT4 dosage. This trial demonstrated PBM's effectiveness at a lower fluence combined with supplements in restoring thyroid function and managing weight, marking the first instance of such a finding.
  • Source: MDPI

Other Information

The wavelengths used in these studies, 820 and 850 nm, are within the infrared spectrum. Our TotalSpectrum series devices, emitting at a high intensity of 850 nm, and the 810nm align with the parameters of these studies, suggesting their potential usefulness in the management of Hashimoto's Thyroiditis.

While extensive research has highlighted the benefits of certain wavelengths, such as 820 nm, it is important to understand that the therapeutic effects of PBM are not confined to a single precise wavelength. Instead, the efficacy of PBM exists within a spectrum. The 810 nm wavelength, being very close to 820 nm, falls within this therapeutic window.


The findings from these two human trials present a promising outlook for the use of PBM therapy, particularly at 820 and 850 nm wavelengths, as a supplementary treatment for Hashimoto's Thyroiditis. The therapy has shown effectiveness in improving thyroid function, reducing the need for hormone replacement therapy, and positively impacting various anthropometric and lifestyle factors. The integration of PBM therapy with dietary supplements presents a non-invasive and potentially effective intervention for enhancing thyroid gland function and addressing related symptoms in HT patients.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.